从雷珠单抗转换为阿柏西普后视力改善不能维持
该多中心全国电子病历数据库研究评估长期接受雷珠单抗治疗的新生血管性年龄相关性黄斑变性患者转换为阿柏西普后是否获益。转换组在转换后3个月视力短暂提高0.9个早期治疗糖尿病视网膜病变研究字母,但自转换后4个月起视力下降与对照组相似,视力改善短暂且不能维持。
要点
- 转换至阿柏西普后视力短暂提高,峰值在转换后3个月增加0.9个ETDRS字母。
- 转换后2、3、5个月两组视力差异显著(P < 0.05),但自4个月起转换组视力下降与对照组相似。
- 转换为抗VEGF药物带来的视力改善是短暂且不能维持的,可能对长期维持治疗有启示。
核心结论
- 在抗血管内皮生长因子(VEGF)药物之间转换时,视力出现短暂、不能维持的改善,这可能对长期使用一种抗VEGF药物维持治疗的患者有启示。
研究设计与样本
- 多中心、全国性电子病历数据库研究;连续接受6次每月雷珠单抗注射后转换为连续阿柏西普治疗的患者,与持续雷珠单抗治疗者按2:1比例匹配,匹配依据为转换前6个月和转换时的视力及既往雷珠单抗注射次数。
主要发现
- 转换为阿柏西普的患者视力出现短暂显著改善,峰值在转换后3个月增加0.9个早期治疗糖尿病视网膜病变研究(ETDRS)字母,而持续雷珠单抗治疗的对照组视力稳步下降。
- 转换后2、3、5个月两组视力差异显著(P < 0.05)。
- 自转换后4个月起,转换组视力下降与对照组相似。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To assess whether visual benefits exist in switching to aflibercept in patients who have been chronically treated with ranibizumab for neovascular age-related macular degeneration. METHODS: A multicenter, national, electronic medical record database study was performed. Patients undergoing six continuous monthly ranibizumab injections and then switched to continuous aflibercept were matched to those on continuous ranibizumab therapy. Matching was performed in a 2:1 ratio and based on visual acuity 6 months before and at the time of the switch, and the number of previous ranibizumab injections. RESULTS: Patients who were switched to aflibercept demonstrated transiently significant improvement in visual acuity that peaked at an increase of 0.9 Early Treatment Diabetic Retinopathy Study letters 3 months after the switch, whereas control patients continued on ranibizumab treatment showed a steady decline in visual acuity. Visual acuity differences between the groups were significant (P < 0.05) at 2, 3, and 5 months after the switch. Beginning at 4 months after the switch, the switch group showed a visual acuity decline similar to the control group. CONCLUSION: Transient, nonsustained improvement in visual acuity occurs when switching between anti-vascular endothelial growth factor agents, which may have implications in treating patients on chronic maintenance therapy on one anti-vascular endothelial growth factor medication.
引用
- Lee CS, Kim AJ, Baughman D, et al. VISUAL ACUITY IMPROVEMENT WHEN SWITCHING FROM RANIBIZUMAB TO AFLIBERCEPT IS NOT SUSTAINED. Retina. 2018. PMID: 28406859. doi:10.1097/IAE.0000000000001637
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。